Landmark studies: Difference between revisions
Jump to navigation
Jump to search
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| Line 49: | Line 49: | ||
* REDEEM Lancet 2012 (dutasteride in AS progression) | * REDEEM Lancet 2012 (dutasteride in AS progression) | ||
==== Radical prostatectomy ==== | |||
* Antibiotic prophylaxis at the time of catheter removal after radical prostatectomy | * Antibiotic prophylaxis at the time of catheter removal after radical prostatectomy | ||
==== Radiation and ADT ==== | |||
* EORTC 22863 NEJM 1997 (EBRT +/- 3 years ADT) | * EORTC 22863 NEJM 1997 (EBRT +/- 3 years ADT) | ||
| Line 62: | Line 62: | ||
* SPCG-7/SFUO-3 | * SPCG-7/SFUO-3 | ||
==== | ==== Post-prostatectomy radiation ==== | ||
* Adjuvant vs. Observation | |||
**[https://test.urologyschool.com/index.php/Prostate_Cancer:_Management_of_Locally_Advanced_Prostate_Cancer#Southwest_Oncology_Group_(SWOG)_8794 SWOG 8794] | |||
**[https://test.urologyschool.com/index.php/Prostate_Cancer:_Management_of_Locally_Advanced_Prostate_Cancer#European_Organization_for_Research_and_Treatment_of_Cancer_(EORTC)_22911 EORTC 22911] | |||
**[https://test.urologyschool.com/index.php/Prostate_Cancer:_Management_of_Locally_Advanced_Prostate_Cancer#ARO_96-02 ARO 96-02] | |||
*ARTISTIC Lancet 2020 (meta-analysis of adjuvant vs. salvage) | |||
*RADICALS Lancet 2020 (adjuvant vs. salvage) | |||
==== Metastatic Hormone-Sensitive Prostate Cancer ==== | |||
* CHAARTED NEJM 2015 (docetaxel) | * CHAARTED NEJM 2015 (docetaxel) | ||
| Line 80: | Line 83: | ||
*[https://test.urologyschool.com/index.php/Hormonal_Therapy#LHRH_antagonists HERO NEJM 2020 (LHRH antagonist)] | *[https://test.urologyschool.com/index.php/Hormonal_Therapy#LHRH_antagonists HERO NEJM 2020 (LHRH antagonist)] | ||
==== Castrate-Resistant Prostate Cancer ==== | |||
===== Non-metastatic ===== | |||
* ARAMIS NEJM 2018 (darolutamide) | * ARAMIS NEJM 2018 (darolutamide) | ||
| Line 88: | Line 91: | ||
* PROSPER NEJM 2018 (enzalutamide) | * PROSPER NEJM 2018 (enzalutamide) | ||
===== Metastatic ===== | |||
Pre-docetaxel | Pre-docetaxel | ||
Revision as of 17:14, 18 March 2024
Oncology
Prostate Cancer
Prevention
- PCPT 2003 (Finasteride)
- SELECT 2009 (Selenium and Vitamin E)
- REDUCE 2010 (Dutasteride)
Screening
- PLCO 2008
- ERSPC 2009
- Goteburg 2010
- CAP 2018
Diagnosis and Evalutation
- MRI PROMIS 2017
- PRECISION 2018
- MRI-FIRST 2019
- ASIST 2019 (MRI in AS)
- STHLM3 NEJM 2021 (MRI-targetted vs. standard biopsy in prostate cancer screening)
- PET proPSMA 2020
PSA and Other Markers
- Stamey et al. NEJM 1987
- Catalona et al. NEJM 1991
- Catalona et al. J Urol 1994 (PSA vs. DRE detection in screening)
- Catalona et al. 1998 (%fPSA)
Prostate Biopsy
- Antibiotic Prophylaxis in TRUS Biopsy of the Prostate Cochrane Review 2011
- Rates of hospital admission and mortality after TRUS-biopsy J Urol 2013
Management of Localized Disease
Observation vs. Treatment of Prostate Cancer
- PIVOT NEJM 2012
- SPCG-4 NEJM 2014
- PROTECT NEJM 2016
Active surveillance
- REDEEM Lancet 2012 (dutasteride in AS progression)
Radical prostatectomy
- Antibiotic prophylaxis at the time of catheter removal after radical prostatectomy
Radiation and ADT
- EORTC 22863 NEJM 1997 (EBRT +/- 3 years ADT)
- RTOG 86-10 (EBRT +/- 4 months ADT)
- RTOG 92-02
- EORTC 22961
- PR3/PR07
- SPCG-7/SFUO-3
Post-prostatectomy radiation
- Adjuvant vs. Observation
- ARTISTIC Lancet 2020 (meta-analysis of adjuvant vs. salvage)
- RADICALS Lancet 2020 (adjuvant vs. salvage)
Metastatic Hormone-Sensitive Prostate Cancer
- CHAARTED NEJM 2015 (docetaxel)
- STAMPEDE Lancet 2016 (docetaxel)
- STAMPEDE NEJM 2017 (abiraterone)
- LATITUDE NEJM 2017 (abiraterone)
- STAMPEDE Lancet 2018 (radiation)
- ENZAMET NEJM 2019 (enzalutamide)
- ARCHES JCO 2019 (enzalutamide)
- TITAN NEJM 2019 (enzalutamide)
- HERO NEJM 2020 (LHRH antagonist)
Castrate-Resistant Prostate Cancer
Non-metastatic
- ARAMIS NEJM 2018 (darolutamide)
- SPARTAN NEJM 2018 (apalutamide)
- PROSPER NEJM 2018 (enzalutamide)
Metastatic
Pre-docetaxel
- AFFIRM NEJM 2012 (enzalutamide)
- PREVAIL NEJM 2014 (enzalutamide)
- COU-AA-302
- TAX-327
- IMPACT
Post-docetaxel
- COU-AA-301
- VISION (177Lu-PSMA-617)
- PROfound NEJM 2020 (Olaparib)
- Denosumab vs. zoledronate
- TheraP (177Lu-PSMA-617 vs. cabazitaxel)
- ALSYMPCA (Radium-223)
Incidence of germline mutations in genes mediating DNA-repair processes in prostate cancer NEJM 2016
Kidney Cancer
- EORTC 30904 Partial vs. Radical Nephrectomy
- EORTC 30811 Eur Urol 2009 LND for cN0 suspected RCC
Cytoreductive nephrectomy
- SWOG 8949 IFN-α vs. CN + IFN-α vs.
- EORTC 30947 IFN-α vs. CN + IFN-α
- SURTIME JAMA Onc 2019 CN + sunitnib vs. sunitnib + CN
- CARMENA NEJM 2018 sunitnib vs. CN + sunitnib
Systemic treatment for metastatic disease
- CheckMate 214 NEJM 2018 (nivolumab + ipilimumab vs. sunitnib for untreated, advanced clear-cell RCC)
- CheckMate 9ER NEJM 2020 (nivolumab + cabozantinib vs. sunitnib for untreated, advanced clear-cell RCC)
- CLEAR NEJM 2021 (lenvatinib + pembrolizumab vs. lenvatinib + everolimus vs. sunitinib)
Adjuvant therapy after nephrectomy
- ASSURE Lancet 2016 (sunitnib vs. sorafenib)
- S-TRAC (sunitnib)
- KEYNOTE-564 (pembrolizumab)
Bladder Cancer
NMIBC
Intravesical Therapy
Chemotherapy
- Meta-analysis of trials evaluating chemotherapy on risk of NMIBC recurrence 2013
BCG
- SWOG 8216/38 NEJM 1991 (BCG vs. doxorubicin BCG maintenance)
- SWOG 8507 J Urol 2000 (induction vs. induction + maintenance BCG)
- BCG and NMIBC Recurrence Cochrane Review 2000
- BCG and NMIBC Progression Meta-analaysis 2002
- BCG vs. MMC in NMIBC Cochrane Review 2003
BCG unresponsive NMIBC
- KEYNOTE-057 (pembrolizumab for BCG-unresponsive CIS)
MIBC
Neoadjuvant Chemotherapy
Immunotherapy
Cystectomy
Systemic treatment for locally advanced, unresectable, or metastatic disease
- KEYNOTE-361 Lancet Onc 2021 (pembrolizumab + chemotherapy vs. chemotherapy alone vs. pembrolizumab alone)
Upper tract urothelial carcinoma
- Olympus Lancet Onc 2020 (UGN-101 for papillary UTUC)
Non-Oncology
Andrology
- Testosterone Deficiency
- Peyronie's Disease
Functional
- TOMUS (retropubic vs. transobturator MUS)
- MTOPS (combination alpha-blocker + 5ARI)
- CombAT (combination alpha-blocker + 5ARI)
Pediatrics
- RIVUR NEJM 2014 (antibiotic prophylaxis in VUR)
Other
- Mechanical Bowel Preparation for Elective Colorectal Surgery Cochrane Review 2011